STRATA CRITICAL MEDICAL INC (NASDAQ:SRTA) Reports Q3 2025 Revenue Beat and Widened Loss

Strata Critical Medical Inc (NASDAQ:SRTA) reported financial results for the third quarter of 2025, delivering a significant revenue beat against analyst expectations while its net loss widened compared to the prior year. The company's performance presents a mixed picture of robust top-line growth against a backdrop of ongoing investments and one-time charges impacting profitability.

Quarterly Performance Versus Estimates

The medical logistics provider posted third-quarter revenue of $49.3 million, representing a substantial 36.7% increase year-over-year. This figure comfortably exceeded the analyst consensus estimate of $44.88 million. When excluding contributions from the recently acquired Keystone Perfusion, organic revenue growth remained strong at 29.0%.

On the profitability front, the company reported a non-GAAP earnings per share of -$0.06, which fell short of the analyst estimate of -$0.0255. The wider-than-expected loss reflects several factors including increased operating expenses and one-time items.

Key financial highlights from the quarter include:

• Revenue of $49.3 million (36.7% YoY growth, beating estimates by ~10%)
• Non-GAAP EPS of -$0.06 (missing estimates by $0.0345)
• Medical Segment Adjusted EBITDA increased 93.5% to $7.6 million
• Gross margin expanded to 19.4% from 15.0% in the prior year period
• Net loss from continuing operations of $(9.7) million versus $(5.6) million in Q3 2024

Market Reaction and Price Action

Following the earnings release, the market has shown a notably positive reaction. In pre-market trading, SRTA shares were up approximately 4.5%, suggesting investors are focusing on the strong revenue beat and raised guidance rather than the earnings miss. This positive momentum contrasts with the stock's recent performance, which saw declines over the past week, month, and two-week period leading up to the earnings announcement.

Strategic Developments and Business Highlights

The quarter represented a transformative period for the company, marked by two significant corporate actions. The company completed the divestiture of its Blade Passenger business to Joby Aviation and closed the acquisition of Keystone Perfusion, establishing what management describes as an "end-to-end organ recovery platform."

Other notable developments include:

• Rebranding from Blade Air Mobility to Strata Critical Medical with ticker symbol change to SRTA
• Raising full-year 2025 revenue guidance to $185-195 million from previous guidance of $180-190 million
• Reaffirming 2025 Adjusted EBITDA guidance of $13-14 million
• Announcing an Investor Day scheduled for November 17th, 2025 to introduce 2026 guidance

Forward Outlook and Analyst Expectations

The company's raised revenue guidance of $185-195 million for full-year 2025 positions it well against current analyst sales estimates of $213.54 million. For the upcoming fourth quarter, analysts are projecting revenue of $59.16 million and EPS of -$0.0051. Management's decision to raise full-year revenue guidance while maintaining EBITDA targets suggests confidence in the company's growth trajectory and operational efficiency.

Management commentary highlighted "record Adjusted EBITDA performance" and noted that organic growth "accelerated to 29.0% in Q3, well above our expectation for mid-teens revenue growth in the second half of the year."

For a detailed look at historical earnings performance and future estimates for Strata Critical Medical, view the complete earnings and estimates data here.

Disclaimer: This article provides financial analysis for informational purposes only and should not be construed as investment advice. All investment decisions should be based on your own research, experience, and financial objectives.